Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Tyra Biosciences, Inc.NASDAQ: TYRA
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 10.8% from a year ago
Property, plant & equipment (net) stood at $6.66M at the end of Q1 FY2026, down 10.8% from a year earlier and down 3.3% from the prior quarter. Over 3 fiscal years it compounded at +24.8% a year.
Context
- Property, plant & equipment (net) amounted to 1.6% of total assets at the end of Q1 FY2026, down 0.6 pp from a year earlier.
- Property, plant & equipment (net) increased in 1 of the last 3 fiscal years.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -10.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 6.89M USD
- Year-over-year change
- -10.8%
- 4-year CAGR
- +34.7%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.89M | -10.8% |
| FY2024 | 2024-12-31 | 7.72M | -5.3% |
| FY2023 | 2023-12-31 | 8.15M | +130.1% |
| FY2022 | 2022-12-31 | 3.54M | +69.6% |
| FY2021 | 2021-12-31 | 2.09M | — |
Property, Plant & Equipment (Net) vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's Mar 2026 property, plant & equipment (net) of $6.66M is the 5th highest of the 11 companies compared; the peer median is $3.37M.
- Its year-over-year change of -10.8% is the 8th highest of 11, against a peer median of +15.3%.
- Property, plant & equipment (net) amounts to 1.6% of total assets for TYRA, versus a peer median of 1.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $33.97M | -17.1% | -14.5% | 15.6% | |
| Mar 2026 | $32.1M | +1.8% | -12.7% | 14.4% | |
| Mar 2026 | $21.42M | -10.1% | -8.8% | 2.1% | |
| Mar 2026 | $14.78M | +40.9% | +33.4% | 2.3% | |
| Mar 2026 | $6.66M | -10.8% | +24.8% | 1.6% | |
| Jun 2026 | $3.96M | -24.8% | -1.5% | 0.5% | |
| Mar 2026 | $2.79M | +130.8% | -36.1% | 1.2% | |
| Mar 2026 | $2.78M | +28.8% | -16.8% | 0.7% | |
| Mar 2026 | $2.15M | -28.9% | -14.0% | 0.5% | |
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $1.77M | +157.8% | +47.3% | 0.3% |
| Mar 2026 | $370K | +208.3% | -54.6% | 0.1% | |
| Peer median (excluding TYRA) | $3.37M | +15.3% | -13.3% | 1.0% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 302.18M | 251.21M | 58.01M | 91.97M | 77.39M |
| Short-term Investments | 0 | 0 | 145.46M | 249.48M | 178.62M |
| Net Receivables | 0 | 0 | 0 | 2M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 6.08M | 8.2M | 4.02M | 9.45M |
| Total Current Assets | 304.06M | 257.29M | 211.67M | 347.46M | 265.45M |
| Property, Plant & Equipment (Net) | 2.09M | 3.54M | 8.15M | 7.72M | 6.89M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 555K | 5.35M | 6.03M | 8.38M | 10.27M |
| Total Non-current Assets | 2.64M | 8.89M | 14.19M | 16.1M | 17.16M |
| Total Assets | 306.7M | 266.18M | 225.86M | 363.56M | 282.61M |
| Account Payables | 599K | 1.15M | 4.66M | 590K | 1.18M |
| Short-term Debt | 0 | 0 | 0 | 412K | 472K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 5.27M | 7.14M | 10.91M |
| Total Current Liabilities | 3.62M | 5.7M | 15.33M | 14.59M | 18.09M |
| Long-term Debt | 0 | 0 | 0 | 0 | 5.34M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 367K | 169K | 46K | 3K | 0 |
| Total Non-current Liabilities | 1.35M | 2.65M | 6.26M | 5.81M | 5.34M |
| Total Liabilities | 4.96M | 8.35M | 21.6M | 20.41M | 23.43M |
| Common Stock | 4K | 4K | 4K | 5K | 5K |
| Retained Earnings | (40.37M) | (95.7M) | (164.83M) | (251.31M) | (371.26M) |
| Accumulated OCI | 0 | 0 | 381K | 770K | 393K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 301.74M | 257.83M | 204.26M | 343.15M | 259.18M |
| Total Debt | 1.18M | 2.62M | 6.5M | 6.22M | 5.81M |
| Net Debt | (301M) | (248.59M) | (51.51M) | (85.74M) | (71.58M) |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.